Combinations of proteasome inhibitors and cyclic peptides
AssigneeBig Dna Ltd
InventorsJohn Bernard March, Ewan McIntosh Clark
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination comprising a proteasome inhibitor and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. In particular, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: a boronate, an epoxyketone, a peptide aldehyde and a β-lactone protease inhibitor; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. More particularly, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: bortezomib, delanzomib, ixazomib, carfilzomib, oprozomib, MG132 and marizomib; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety.
Claims23
A combination comprising:
- (i) a proteasome inhibitor or a pharmaceutically acceptable salt thereof;
- and (ii) a cyclic peptide or a pharmaceutically acceptable salt thereof, wherein the cyclic peptide or a pharmaceutically acceptable salt thereof comprises an exposed Arg-Gly-Asp (RGD) moiety;
- and wherein the ratio of the proteasome inhibitor or a pharmaceutically acceptable salt thereof to the cyclic peptide or a pharmaceutically acceptable salt thereof ranges from 1:5000 to 1:10 w/w.
A kit comprising as separate components:
- (i) a proteasome inhibitor or a pharmaceutically acceptable salt thereof;
- and (ii) a cyclic peptide or a pharmaceutically acceptable salt thereof, wherein the cyclic peptide or a pharmaceutically acceptable salt thereof comprises an exposed Arg-Gly-Asp (RGD) moiety.
Dependencies are inferred from the claim text.